Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Comparative Post-marketing Study of Commercially Available Peripheral Nerve Gap Repair Options (CHANGE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00948025
Recruitment Status : Terminated (transitioning from 361 HCT/P Tissue to a Biologic (BLA))
First Posted : July 29, 2009
Results First Posted : December 1, 2020
Last Update Posted : December 1, 2020
Sponsor:
Information provided by (Responsible Party):
Axogen Corporation

Brief Summary:
This study is a comparison of sensory recovery outcomes following the use of AVANCE Nerve Graft or hollow tube conduit for peripheral nerve gap repairs in the hand.

Condition or disease Intervention/treatment Phase
Traumatic Nerve Injury Device: Hollow tube nerve conduit, synthetic or biosynthetic Other: Processed Human Nerve Tissue Not Applicable

Detailed Description:

The CHANGE study is a post-marketing study designed as a prospective, single-blind, randomized, two phase study comparing clinical outcomes of AVANCE Nerve Graft to hollow tube conduits. The first phase (pilot phase) assesses projected differences expected between two treatment groups. The second phase of the study provides comparison data between the two treatment groups.

AVANCE Nerve Graft is current regulated in the United States as a 361 HCT/P Tissue for transplantation; not a Drug, Biologic, or Medical Device. Hollow tube conduits are currently regulated in the United States as medical devices.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 23 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Prospective, Randomized, Comparative Study of Hollow Nerve Conduit and Avance Nerve Graft Evaluating Recovery Outcomes of Nerve Repair in the Hand. (CHANGE)
Actual Study Start Date : June 2009
Actual Primary Completion Date : December 2014
Actual Study Completion Date : December 2014

Arm Intervention/treatment
Active Comparator: Avance Nerve Graft
Commercially available Avance Nerve Graft for repair of nerve gap
Other: Processed Human Nerve Tissue
Implantation of appropriate length of processed human nerve tissue at time of surgery.
Other Name: Avance Nerve Graft

Active Comparator: Hollow Tube Conduit
Commercially available hollow tube conduit for repair of nerve gap.
Device: Hollow tube nerve conduit, synthetic or biosynthetic
Appropriately size matched hollow tube nerve conduit (Neurotube, NeuroLac, NeuraGen, NeuroMatrix, NeuroFlex)
Other Names:
  • Neurotube
  • NeuroLac
  • NeuraGen
  • NeuroMatrix
  • NeuroFlex




Primary Outcome Measures :
  1. Recovery of Static 2-point Discrimination in the Affected Digit [ Time Frame: 12 Months ]
    Mean change in static 2-Point Discrimination between baseline and 12 months


Secondary Outcome Measures :
  1. Moving 2-point Discrimination [ Time Frame: 12 months ]
    Percent Change from Baseline of Moving 2-Point Discriminations at Month 12

  2. Semmes-Weinstein Monofilament Assessment [ Time Frame: 12 months ]
    Percent Change from Baseline of Semmes-Weinstein Monofilament Assessment at Month 12

  3. 12-month DASH Core Module Scores [ Time Frame: 12 months ]

    Summary of Disability of the Arm, Shoulder, and Hand (DASH) scores (Core Module) at Month 12

    The Disabilities of the Arm, Shoulder and Hand (DASH) core module questionnaire is a 30-item questionnaire includes 21 physical function items, 6 symptom items, and 3 social/role function items. It is a patient reported questionnaire used to assess physical function and severity of symptoms in patients with musculoskeletal disorders of the upper limb. Each of the items in the DASH use a 5-point Likert scale to assess the corresponding severity or functional parameter. The outcome measure is scored based on the formula ([sum of n responses)/ - 30 (minimum score]/1.2 (range of scores ÷100), where n represents the number of completed items. Computed scores range from 0 (no disability) to 100 (most severe disability).


  4. 12-month DASH (Work Module) Scores [ Time Frame: 12 month ]

    Summary of Disability of the Arm, Shoulder, and Hand (DASH) scores (Work Module) at Month 12

    The Disabilities of the Arm, Shoulder and Hand (DASH) Work Module questionnaire is a 4-item questionnaire used to identify the job-specific difficulties that workers might experience but which may not affect their activities of daily living. It is a patient reported questionnaire used to assess the impact that musculoskeletal disorders of the upper limb have on a patient's ability to perform work-related tasks. Each of the items in the DASH Work Module use a 5-point Likert scale to assess the corresponding severity or functional parameter. The outcome measure is scored based on the formula ([sum of n responses)/ - 4 (minimum score]/0.16 (range of scores ÷100), where n represents the number of completed items. Computed scores range from 0 (no difficulty) to 100 (most severe difficulty).


  5. 12- Month DASH (Sports/Performing Arts Module) [ Time Frame: 12 months ]

    Summary of Disability of the Arm, Shoulder, and Hand (DASH) scores (Sports/Performing Arts Module) at month 12

    The Disabilities of the Arm, Shoulder and Hand (DASH) Sports/Performing Arts Module questionnaire is a 4-item questionnaire used to identify the specific difficulties that professional athletes/performing artists might experience but which may not affect their activities of daily living. It is a patient reported questionnaire used to assess the impact that musculoskeletal disorders of the upper limb have on a patient's ability to perform sports or play a musical instrument. Each of the items in the DASH use a 5-point Likert scale to assess the corresponding severity or functional parameter. The outcome measure is scored based on the formula ([sum of n responses)/ - 4 (minimum score]/0.16 (range of scores ÷100), where n represents the number of completed items. Computed scores range from 0 (no difficulty) to 100 (most severe difficulty).


  6. Pain at 12-months [ Time Frame: 12-months ]

    Summary of Pain Assessment using Visual Analogue Scale (VAS) at Month 12

    The Visual Analog Scale (VAS) For Pain is a patient reported outcomes scale whereby the patient indicates his/her current pain level by making a mark on a continuous horizontal 10 centimeter (100 millimeter) line. The distance from the 0 millimeter to the patient's mark corresponds to the amount of pain the subject is currently experiencing. VAS for Pain data are recorded as the number of millimeters from the left of the line to the patients mark across the range of 0-100 millimeters, with 0 millimeter representing no pain and 100 millimeters representing "the worst pain imaginable".


  7. Thermal Discretion at 12-months [ Time Frame: 12-month ]

    Summary of Thermal Discretion at Month 12 as determined by the Investigator.

    Thermal discretion was assessed by applying a hot and/or cold object to the patient's affected digit. Thermal discretion was reported as either present ("Yes") or not present ("No").


  8. Protective Sensation Present at 12-months [ Time Frame: 12 months ]

    Summary of Protective Sensation by Month 12

    Semmes-Weinstein Monofilament (SWMF) assessment of protective sensation. The gauge of the monofilaments range from 2.83 (normal) to 6.65 (deep pressure sensation only). Protective Sensation Present (SWMF score of 3.61 or better), Protective Sensation Diminished (SWMF score of 4.31-3.84), Protective Sensation Absent (SWMF score of 4.56 or greater).


  9. Functional Recovery Classification (Medical Research Council Evaluation of Sensory Function) at 12-months [ Time Frame: 12 months ]

    Summary of Functional Recovery Classification (Medical Research Council Evaluation of Sensory Function) at 12-months

    Patients were assessed for functional recovery of sensation on a scale from S0 to S4 with S0 representing absence of sensibility, S1 representing recovery of deep cutaneous pain sensibility, S2 representing the return of some degree of superficial cutaneous pain and tactile sensibility, S3 representing return of superficial cutaneous pain and tactile sensibility, S3+ representing return of sensibility as in S3 and some recovery of 2-point discrimination (a 2-PD score between 7-15mm), and S4 representing complete recovery of normal sensation as assessed by 2-point discrimination (score between 2-6mm).




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Require primary or secondary nerve injury repair with Hollow Nerve Conduit or AVANCE™ in at least 1 digital nerve;
  • Undergo End to End nerve to nerve graft coaptation on both the proximal and distal portion of the nerve gap in the AVANCE™ group or nerve entubulation in the Hollow Nerve Conduit group;
  • Be willing to comply with all aspects of the treatment and evaluation schedule over a 12 Month duration; and
  • Sign and date an IRB-approved written informed consent prior to initiation of any study procedures, including screening procedures.

Exclusion Criteria:

  • Nerve gaps of < 5 mm or > 20 mm;
  • Estimated distance of regeneration of >125 mm (distance from injury site to sensory target)
  • Nerve crush or avulsion injuries;
  • Incomplete nerve transections;
  • Injury requiring replantation of target digit;
  • Contralateral digital injuries corresponding to the target digit;
  • Nerve injuries in the affected limb proximal to the crease of the wrist;
  • End to side nerve repair;
  • Injuries with significant vascular damage which may impair adequate perfusion of the target limb;
  • Subjects who are undergoing treatment with chemotherapy, radiation therapy, or other know treatment which affects the growth of neural and/or vascular system;
  • Use of bovine collagen based hollow nerve conduit in a subject with known or suspected bovine sensitivity;
  • Subjects age ≤18 years or ≥70 years;
  • History neuropathy, diabetic or any other known neuropathy;
  • Secondary nerve repair >12 weeks post initial injury;
  • Currently enrolled in another investigational study;
  • Expected use of medications during the study that are known to cause peripheral neuropathy;
  • History or Reynaud's or other disorder known to compromise circulation or sensation in the upper extremity; and
  • Any subject who at the discretion of the Investigator is not suitable for inclusion in the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00948025


Locations
Layout table for location information
United States, Georgia
Georgia Hand, Shoulder and Elbow
Atlanta, Georgia, United States, 30309
United States, Indiana
Indiana Hand Center
Indianapolis, Indiana, United States, 46260
United States, Kentucky
University of Kentucky
Lexington, Kentucky, United States, 40536
United States, Maryland
Curtis National Hand Center
Baltimore, Maryland, United States, 21218
Sponsors and Collaborators
Axogen Corporation
Investigators
Layout table for investigator information
Study Director: Erick W DeVinney Axogen Corporation
Layout table for additonal information
Responsible Party: Axogen Corporation
ClinicalTrials.gov Identifier: NCT00948025    
Other Study ID Numbers: ANG-CP-004
First Posted: July 29, 2009    Key Record Dates
Results First Posted: December 1, 2020
Last Update Posted: December 1, 2020
Last Verified: November 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: IPD will not be released to other researchers.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by Axogen Corporation:
Peripheral Nerve Repair
Conduit
AVANCE
Neuroma Resection
Nerve Gap Repair
Digital Nerve Repair
Nerve Graft
Nerve Allograft